REDCARE PHARMACY NV (RDC.DE) Fundamental Analysis & Valuation

FRA:RDC • NL0012044747

47.02 EUR
-12.48 (-20.97%)
Last: Mar 4, 2026, 05:28 PM

This RDC.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, RDC scores 3 out of 10 in our fundamental rating. RDC was compared to 25 industry peers in the Consumer Staples Distribution & Retail industry. While RDC seems to be doing ok healthwise, there are quite some concerns on its profitability. RDC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. RDC.DE Profitability Analysis

1.1 Basic Checks

  • In the past year RDC has reported negative net income.
  • RDC had a positive operating cash flow in the past year.
  • In the past 5 years RDC always reported negative net income.
  • RDC had a positive operating cash flow in 4 of the past 5 years.
RDC.DE Yearly Net Income VS EBIT VS OCF VS FCFRDC.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • With a Return On Assets value of -2.88%, RDC is not doing good in the industry: 72.00% of the companies in the same industry are doing better.
  • Looking at the Return On Equity, with a value of -7.01%, RDC is doing worse than 72.00% of the companies in the same industry.
Industry RankSector Rank
ROA -2.88%
ROE -7.01%
ROIC N/A
ROA(3y)-5.45%
ROA(5y)-5.79%
ROE(3y)-11.19%
ROE(5y)-11.08%
ROIC(3y)N/A
ROIC(5y)N/A
RDC.DE Yearly ROA, ROE, ROICRDC.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5 -10 -15 -20

1.3 Margins

  • The Gross Margin of RDC (22.88%) is comparable to the rest of the industry.
  • RDC's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for RDC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 22.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.88%
GM growth 5Y3.23%
RDC.DE Yearly Profit, Operating, Gross MarginsRDC.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

5

2. RDC.DE Health Analysis

2.1 Basic Checks

  • RDC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • RDC has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for RDC has been increased compared to 5 years ago.
  • Compared to 1 year ago, RDC has a worse debt to assets ratio.
RDC.DE Yearly Shares OutstandingRDC.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
RDC.DE Yearly Total Debt VS Total AssetsRDC.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • RDC has an Altman-Z score of 3.21. This indicates that RDC is financially healthy and has little risk of bankruptcy at the moment.
  • RDC has a Altman-Z score of 3.21. This is in the better half of the industry: RDC outperforms 68.00% of its industry peers.
  • RDC has a Debt/Equity ratio of 0.62. This is a neutral value indicating RDC is somewhat dependend on debt financing.
  • The Debt to Equity ratio of RDC (0.62) is better than 80.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Altman-Z 3.21
ROIC/WACCN/A
WACC6.45%
RDC.DE Yearly LT Debt VS Equity VS FCFRDC.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 1.68 indicates that RDC should not have too much problems paying its short term obligations.
  • RDC's Current ratio of 1.68 is amongst the best of the industry. RDC outperforms 92.00% of its industry peers.
  • A Quick Ratio of 1.23 indicates that RDC should not have too much problems paying its short term obligations.
  • The Quick ratio of RDC (1.23) is better than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.68
Quick Ratio 1.23
RDC.DE Yearly Current Assets VS Current LiabilitesRDC.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

6

3. RDC.DE Growth Analysis

3.1 Past

  • RDC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -39.61%.
  • RDC shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.68%.
  • Measured over the past years, RDC shows a very strong growth in Revenue. The Revenue has been growing by 27.59% on average per year.
EPS 1Y (TTM)-39.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.86%
Revenue 1Y (TTM)26.68%
Revenue growth 3Y30.76%
Revenue growth 5Y27.59%
Sales Q2Q%25.18%

3.2 Future

  • The Earnings Per Share is expected to grow by 50.88% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 18.19% on average over the next years. This is quite good.
EPS Next Y48.65%
EPS Next 2Y45.01%
EPS Next 3Y45.59%
EPS Next 5Y50.88%
Revenue Next Year24.2%
Revenue Next 2Y21.34%
Revenue Next 3Y19.47%
Revenue Next 5Y18.19%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RDC.DE Yearly Revenue VS EstimatesRDC.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B
RDC.DE Yearly EPS VS EstimatesRDC.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 5 10

1

4. RDC.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • RDC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 237.26 indicates a quite expensive valuation of RDC.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of RDC indicates a rather expensive valuation: RDC more expensive than 84.00% of the companies listed in the same industry.
  • RDC's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.11.
Industry RankSector Rank
PE N/A
Fwd PE 237.26
RDC.DE Price Earnings VS Forward Price EarningsRDC.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200

4.2 Price Multiples

  • 80.00% of the companies in the same industry are cheaper than RDC, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 33.45
RDC.DE Per share dataRDC.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • A more expensive valuation may be justified as RDC's earnings are expected to grow with 45.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.01%
EPS Next 3Y45.59%

0

5. RDC.DE Dividend Analysis

5.1 Amount

  • RDC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

RDC.DE Fundamentals: All Metrics, Ratios and Statistics

REDCARE PHARMACY NV

FRA:RDC (3/4/2026, 5:28:47 PM)

47.02

-12.48 (-20.97%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)10-29
Earnings (Next)03-04
Inst Owners51.62%
Inst Owner ChangeN/A
Ins Owners7.32%
Ins Owner ChangeN/A
Market Cap967.67M
Revenue(TTM)2.82B
Net Income(TTM)-35.19M
Analysts80
Price Target131.3 (179.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)150.51%
Min EPS beat(2)-12.8%
Max EPS beat(2)313.82%
EPS beat(4)2
Avg EPS beat(4)71.29%
Min EPS beat(4)-42.68%
Max EPS beat(4)313.82%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.34%
Min Revenue beat(2)-1.55%
Max Revenue beat(2)-1.13%
Revenue beat(4)0
Avg Revenue beat(4)-1.42%
Min Revenue beat(4)-2.24%
Max Revenue beat(4)-0.77%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.9%
PT rev (3m)-10.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.06%
Revenue NQ rev (1m)-0.37%
Revenue NQ rev (3m)-2.12%
Revenue NY rev (1m)-0.7%
Revenue NY rev (3m)-1.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 237.26
P/S 0.34
P/FCF N/A
P/OCF 29.49
P/B 1.93
P/tB 9.72
EV/EBITDA 33.45
EPS(TTM)-1.75
EYN/A
EPS(NY)0.2
Fwd EY0.42%
FCF(TTM)-2.99
FCFYN/A
OCF(TTM)1.59
OCFY3.39%
SpS137.07
BVpS24.41
TBVpS4.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.88%
ROE -7.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 22.88%
FCFM N/A
ROA(3y)-5.45%
ROA(5y)-5.79%
ROE(3y)-11.19%
ROE(5y)-11.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.88%
GM growth 5Y3.23%
F-Score3
Asset Turnover2.31
Health
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Debt/EBITDA 8.5
Cap/Depr 136.74%
Cap/Sales 3.34%
Interest Coverage N/A
Cash Conversion 90.05%
Profit Quality N/A
Current Ratio 1.68
Quick Ratio 1.23
Altman-Z 3.21
F-Score3
WACC6.45%
ROIC/WACCN/A
Cap/Depr(3y)87.99%
Cap/Depr(5y)151.24%
Cap/Sales(3y)2.78%
Cap/Sales(5y)3.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.86%
EPS Next Y48.65%
EPS Next 2Y45.01%
EPS Next 3Y45.59%
EPS Next 5Y50.88%
Revenue 1Y (TTM)26.68%
Revenue growth 3Y30.76%
Revenue growth 5Y27.59%
Sales Q2Q%25.18%
Revenue Next Year24.2%
Revenue Next 2Y21.34%
Revenue Next 3Y19.47%
Revenue Next 5Y18.19%
EBIT growth 1Y-72.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year290.79%
EBIT Next 3Y91.37%
EBIT Next 5Y59.12%
FCF growth 1Y-2656.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.32%
OCF growth 3Y23.87%
OCF growth 5YN/A

REDCARE PHARMACY NV / RDC.DE FAQ

What is the ChartMill fundamental rating of REDCARE PHARMACY NV (RDC.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RDC.DE.


Can you provide the valuation status for REDCARE PHARMACY NV?

ChartMill assigns a valuation rating of 1 / 10 to REDCARE PHARMACY NV (RDC.DE). This can be considered as Overvalued.


Can you provide the profitability details for REDCARE PHARMACY NV?

REDCARE PHARMACY NV (RDC.DE) has a profitability rating of 2 / 10.


What is the expected EPS growth for REDCARE PHARMACY NV (RDC.DE) stock?

The Earnings per Share (EPS) of REDCARE PHARMACY NV (RDC.DE) is expected to grow by 48.65% in the next year.